骨髓增生异常综合征患者N-ras基因突变的连续观察  

Consecutive study of N-ras gene mutation in patients with myelodysplastic syndrome

作　　者：马艳青[1] 陈书长[1] 武永吉[1] 吕照江[1] 李德高[1] 葛昌文[1] 沈悌[1] 

机构地区：[1]中国医学科学院,中国协和医科大学北京协和医院血液科,北京100730

出　　处：《中国实验血液学杂志》1998年第2期120-123,共4页Journal of Experimental Hematology

摘　　要：为连续观察骨髓增生异常综合征(MDS)病程进展过程中N-ras基因的突变情况,取19例MDS患者在不同FAB亚型时的骨髓片,每例患者至少取2次不同FAB亚型的骨髓片,应用PCR和寡核苷酸探针斑点杂交技术进行检测。结果显示:MDS患者中N-ras基因突变率为26.0％,主要为G→A的突变;随着MDS病情进展N-ras突变率逐渐增高,突变组比无突变组更易转化为白血病(P<0.05),突变组生存率明显低于无突变组(X^2=4.0149),P<0.05。结论提示,N-ras基因突变可作为观察MDS病程进展和判断其预后的一个指标。For consecutively studying N-ras gene mutations of MDS in the progression, bone marrow smears of 19 cases were detected by PCR and oligonucleotide probe dot-bot hybridization. At least two smears of different subtype of FAB in each patient were analyzed Results showed that the percentage of N-ras mutation in MDS was 26% and G→A mutation was common. It was easier to translate into AML for patients with N-ras mutation than those without N-ras mutation (P<0.05). Survival was significantly shorter in patients with N-ras mutation than those without it (x2 = 4.0149, P<0.05). Conclusion suggested that N-ras mutation can be used as a indication for MDS progression and it' s poor prognosis.

关 键 词：骨髓增生异常综合征 N-RAS基因 基因突变 

分 类 号：R551.3[医药卫生—血液循环系统疾病]